Selected research
Industry Research
Urticaria Drug Industry Research Report 2026
Market perspective
The global Urticaria Drug market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
The North America market for Urticaria Drug is projected to increase from US$ million in 2026 to US$ million by 2032, corresponding to a CAGR of % over 2026–2032.
The Europe market for Urticaria Drug is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032.
Read the full market overview
The Asia Pacific market for Urticaria Drug is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032.
Leading global manufacturers of Urticaria Drug include Akorn, Amneal Pharmaceuticals, Genentech, Taro Pharmaceutical Industries Novartis AG, Xolair, Pfizer, Johnson and Johnson Services and Teva Pharmaceutical Industries, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
This report quantifies the global Urticaria Drug market in terms of revenue (US$ million) and, where applicable, sales volume (K Units), using 2025 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of Types and Applications, harmonizes vendor attribution, and presents comparable time series by company, Type, Application, and region/country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10).
The outputs are intended to support strategy development, budgeting, and performance benchmarking for brand owners, manufacturers, retailers, channel partners, and investors; data are structured with consistent units and fields to facilitate integration into internal FP&A and BI systems.
Key Companies & Market Share Insights
This section profiles leading manufacturers, combining 2021–2025 results with a 2026–2032 outlook. It reports revenue, market share, price bands, product and application mix, regional and channel mix, and key developments (M&A, capacity additions, certifications). It also provides global revenue, average price, and—where applicable—sales volume by manufacturer, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Urticaria Drug Market by Company
Akorn
Amneal Pharmaceuticals
Genentech
Taro Pharmaceutical Industries Novartis AG
Xolair
Pfizer
Johnson and Johnson Services
Teva Pharmaceutical Industries
Urticaria Drug Segment by Type
Acute Urticaria
Chronic Urticaria
Urticaria Drug Segment by Application
Retail Pharmacies
Online Pharmacies
Hospital Pharmacies
Others
Urticaria Drug Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Netherlands
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Urticaria Drug market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Urticaria Drug and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Urticaria Drug.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (by region, product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Detailed analysis of Urticaria Drug manufacturers competitive landscape, price, production and value market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product production/output, value, price, gross margin, product introduction, recent development, etc.
Chapter 5: Production/output, value of Urticaria Drug by region/country. It provides a quantitative analysis of the market size and development potential of each region in the next six years.
Chapter 6: Consumption of Urticaria Drug in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and production of each country in the world.
Chapter 7: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 8: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 10: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 11: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Acute Urticaria
- Chronic Urticaria
Applications
- Retail Pharmacies
- Online Pharmacies
- Hospital Pharmacies
- Others
Companies covered
- Akorn
- Amneal Pharmaceuticals
- Genentech
- Taro Pharmaceutical Industries Novartis AG
- Xolair
- Pfizer
- Johnson and Johnson Services
- Teva Pharmaceutical Industries
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Global Market Growth Prospects
- 2.2.1 Global Urticaria Drug Market Size (2021-2032)
- 2.2.2 Global Urticaria Drug Sales (2021-2032)
- 2.2.3 Global Urticaria Drug Market Average Price (2021-2032)
- 2.3 Urticaria Drug by Type
- 2.3.1 Market Value Comparison by Type (2021 VS 2025 VS 2032) & (US$ Million)
- 2.3.2 Acute Urticaria
- 2.3.3 Chronic Urticaria
- 2.4 Urticaria Drug by Application
- 2.4.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.4.2 Retail Pharmacies
- 2.4.3 Online Pharmacies
- 2.4.4 Hospital Pharmacies
- 2.4.5 Others
3 Market Competitive Landscape by Manufacturers
- 3.1 Global Urticaria Drug Market Competitive Situation by Manufacturers (2021 Versus 2025)
- 3.2 Global Urticaria Drug Sales (K Units) of Manufacturers (2021-2026)
- 3.3 Global Urticaria Drug Revenue of Manufacturers (2021-2026)
- 3.4 Global Urticaria Drug Average Price by Manufacturers (2021-2026)
- 3.5 Global Urticaria Drug Industry Ranking, 2024 VS 2025 VS 2026
- 3.6 Global Manufacturers of Urticaria Drug, Manufacturing Sites & Headquarters
- 3.7 Global Manufacturers of Urticaria Drug, Product Type & Application
- 3.8 Global Manufacturers of Urticaria Drug, Established Date
- 3.9 Global Urticaria Drug Market CR5 and HHI
- 3.10 Global Manufacturers Mergers & Acquisition
4 Manufacturers Profiled
- 4.1 Akorn
- 4.1.1 Akorn Company Information
- 4.1.2 Akorn Business Overview
- 4.1.3 Akorn Urticaria Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.1.4 Akorn Urticaria Drug Product Portfolio
- 4.1.5 Akorn Recent Developments
- 4.2 Amneal Pharmaceuticals
- 4.2.1 Amneal Pharmaceuticals Company Information
- 4.2.2 Amneal Pharmaceuticals Business Overview
- 4.2.3 Amneal Pharmaceuticals Urticaria Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.2.4 Amneal Pharmaceuticals Urticaria Drug Product Portfolio
- 4.2.5 Amneal Pharmaceuticals Recent Developments
- 4.3 Genentech
- 4.3.1 Genentech Company Information
- 4.3.2 Genentech Business Overview
- 4.3.3 Genentech Urticaria Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.3.4 Genentech Urticaria Drug Product Portfolio
- 4.3.5 Genentech Recent Developments
- 4.4 Taro Pharmaceutical Industries Novartis AG
- 4.4.1 Taro Pharmaceutical Industries Novartis AG Company Information
- 4.4.2 Taro Pharmaceutical Industries Novartis AG Business Overview
- 4.4.3 Taro Pharmaceutical Industries Novartis AG Urticaria Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.4.4 Taro Pharmaceutical Industries Novartis AG Urticaria Drug Product Portfolio
- 4.4.5 Taro Pharmaceutical Industries Novartis AG Recent Developments
- 4.5 Xolair
- 4.5.1 Xolair Company Information
- 4.5.2 Xolair Business Overview
- 4.5.3 Xolair Urticaria Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.5.4 Xolair Urticaria Drug Product Portfolio
- 4.5.5 Xolair Recent Developments
- 4.6 Pfizer
- 4.6.1 Pfizer Company Information
- 4.6.2 Pfizer Business Overview
- 4.6.3 Pfizer Urticaria Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.6.4 Pfizer Urticaria Drug Product Portfolio
- 4.6.5 Pfizer Recent Developments
- 4.7 Johnson and Johnson Services
- 4.7.1 Johnson and Johnson Services Company Information
- 4.7.2 Johnson and Johnson Services Business Overview
- 4.7.3 Johnson and Johnson Services Urticaria Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.7.4 Johnson and Johnson Services Urticaria Drug Product Portfolio
- 4.7.5 Johnson and Johnson Services Recent Developments
- 4.8 Teva Pharmaceutical Industries
- 4.8.1 Teva Pharmaceutical Industries Company Information
- 4.8.2 Teva Pharmaceutical Industries Business Overview
- 4.8.3 Teva Pharmaceutical Industries Urticaria Drug Sales, Revenue and Gross Margin (2021-2026)
- 4.8.4 Teva Pharmaceutical Industries Urticaria Drug Product Portfolio
- 4.8.5 Teva Pharmaceutical Industries Recent Developments
5 Global Urticaria Drug Market Scenario by Region
- 5.1 Global Urticaria Drug Market Size by Region: 2021 VS 2025 VS 2032
- 5.2 Global Urticaria Drug Sales by Region: 2021-2032
- 5.2.1 Global Urticaria Drug Sales by Region: 2021-2026
- 5.2.2 Global Urticaria Drug Sales by Region: 2027-2032
- 5.3 Global Urticaria Drug Revenue by Region: 2021-2032
- 5.3.1 Global Urticaria Drug Revenue by Region: 2021-2026
- 5.3.2 Global Urticaria Drug Revenue by Region: 2027-2032
- 5.4 North America Urticaria Drug Market Facts & Figures by Country
- 5.4.1 North America Urticaria Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.4.2 North America Urticaria Drug Sales by Country (2021-2032)
- 5.4.3 North America Urticaria Drug Revenue by Country (2021-2032)
- 5.4.4 United States
- 5.4.5 Canada
- 5.5 Europe Urticaria Drug Market Facts & Figures by Country
- 5.5.1 Europe Urticaria Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.5.2 Europe Urticaria Drug Sales by Country (2021-2032)
- 5.5.3 Europe Urticaria Drug Revenue by Country (2021-2032)
- 5.5.4 Germany
- 5.5.5 France
- 5.5.6 U.K.
- 5.5.7 Italy
- 5.5.8 Netherlands
- 5.6 Asia Pacific Urticaria Drug Market Facts & Figures by Country
- 5.6.1 Asia Pacific Urticaria Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.6.2 Asia Pacific Urticaria Drug Sales by Country (2021-2032)
- 5.6.3 Asia Pacific Urticaria Drug Revenue by Country (2021-2032)
- 5.6.4 China
- 5.6.5 Japan
- 5.6.6 South Korea
- 5.6.7 India
- 5.6.8 Australia
- 5.6.9 China Taiwan
- 5.6.10 Southeast Asia
- 5.7 South America Urticaria Drug Market Facts & Figures by Country
- 5.7.1 South America Urticaria Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.7.2 South America Urticaria Drug Sales by Country (2021-2032)
- 5.7.3 South America Urticaria Drug Revenue by Country (2021-2032)
- 5.7.4 Mexico
- 5.7.5 Brazil
- 5.7.6 Argentina
- 5.8 Middle East and Africa Urticaria Drug Market Facts & Figures by Country
- 5.8.1 Middle East and Africa Urticaria Drug Market Size by Country: 2021 VS 2025 VS 2032
- 5.8.2 Middle East and Africa Urticaria Drug Sales by Country (2021-2032)
- 5.8.3 Middle East and Africa Urticaria Drug Revenue by Country (2021-2032)
- 5.8.4 Turkey
- 5.8.5 Saudi Arabia
- 5.8.6 UAE
6 Segment by Type
- 6.1 Global Urticaria Drug Sales by Type (2021-2032)
- 6.1.1 Global Urticaria Drug Sales by Type (2021-2032) & (K Units)
- 6.1.2 Global Urticaria Drug Sales Market Share by Type (2021-2032)
- 6.2 Global Urticaria Drug Revenue by Type (2021-2032)
- 6.2.1 Global Urticaria Drug Sales by Type (2021-2032) & (US$ Million)
- 6.2.2 Global Urticaria Drug Revenue Market Share by Type (2021-2032)
- 6.3 Global Urticaria Drug Price by Type (2021-2032)
7 Segment by Application
- 7.1 Global Urticaria Drug Sales by Application (2021-2032)
- 7.1.1 Global Urticaria Drug Sales by Application (2021-2032) & (K Units)
- 7.1.2 Global Urticaria Drug Sales Market Share by Application (2021-2032)
- 7.2 Global Urticaria Drug Revenue by Application (2021-2032)
- 7.2.1 Global Urticaria Drug Sales by Application (2021-2032) & (US$ Million)
- 7.2.2 Global Urticaria Drug Revenue Market Share by Application (2021-2032)
- 7.3 Global Urticaria Drug Price by Application (2021-2032)
8 Value Chain and Sales Channels Analysis of the Market
- 8.1 Urticaria Drug Value Chain Analysis
- 8.1.1 Urticaria Drug Key Raw Materials
- 8.1.2 Raw Materials Key Suppliers
- 8.1.3 Urticaria Drug Production Mode & Process
- 8.2 Urticaria Drug Sales Channels Analysis
- 8.2.1 Direct Comparison with Distribution Share
- 8.2.2 Urticaria Drug Distributors
- 8.2.3 Urticaria Drug Customers
9 Global Urticaria Drug Analyzing Market Dynamics
- 9.1 Urticaria Drug Industry Trends
- 9.2 Urticaria Drug Industry Drivers
- 9.3 Urticaria Drug Industry Opportunities and Challenges
- 9.4 Urticaria Drug Industry Restraints
10 Report Conclusion
11 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst